{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:45:44Z","timestamp":1790667944796,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.00458","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T01:33:12Z","timestamp":1592271192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative"],"prefix":"10.3389","volume":"8","author":[{"given":"David F.","family":"Stroncek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoko","family":"Takanashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali J.","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibani","family":"Pati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anna","family":"Reems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3389\/fimmu.2019.02474","article-title":"Multi-parameter analysis of biobanked human bone marrow stromal cells shows little influence for donor age and mild comorbidities on phenotypic and functional properties.","volume":"10","author":"Andrzejewska","year":"2019","journal-title":"Front. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ymthe.2018.05.009","article-title":"Mesenchymal stem cell-based therapy for cardiovascular disease: progress and challenges.","volume":"26","author":"Bagno","year":"2018","journal-title":"Mol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/bjh.12545","article-title":"Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.","volume":"163","author":"Ball","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/trf.15252","article-title":"Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use.","volume":"18","author":"Bieback","year":"2019","journal-title":"Transfusion"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201700085","article-title":"Donor variability in growth kinetics of healthy hMSCs using manual processing: considerations for manufacture of cell therapies.","volume":"13","author":"Detela","year":"2018","journal-title":"Biotechnol. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"B7","article-title":"Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.","volume":"30","author":"Fisher","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tmrv.2015.11.004","article-title":"Unraveling the mesenchymal stromal cells\u2019 paracrine immunomodulatory effects.","volume":"30","author":"Fontaine","year":"2016","journal-title":"Transfusion Med. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000449091","article-title":"Mesenchymal stromal cell therapy in crohn\u2019s disease.","volume":"35","author":"Forbes","year":"2017","journal-title":"Dig Dis."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.","volume":"9","author":"Galleu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/stem.2934","article-title":"Single-cell transcriptomics of human mesenchymal stem cells reveal age-related cellular subpopulation depletion and impaired regenerative function.","volume":"37","author":"Khong","year":"2019","journal-title":"Stem cells."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-38517-7","article-title":"Molecular signature of human bone marrow-derived mesenchymal stromal cell subsets.","volume":"9","author":"Kuci","year":"2019","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s12975-019-00736-5","article-title":"From the lab to patients: a systematic review and meta-analysis of mesenchymal stem cell therapy for stroke.","volume":"25","author":"Lalu","year":"2019","journal-title":"Transl. Stroke Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s0140-6736(08)60690-x","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/s0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"key":"B17","article-title":"Manufacturing differences affect human bone marrow stromal cell characteristics and function: comparison of production methods and products from multiple centers.","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1046\/j.1537-2995.2000.40060693.x","article-title":"HPC viability measurement: trypan blue versus acridine orange and propidium iodide.","volume":"40","author":"Mascotti","year":"2000","journal-title":"Transfusion"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1089\/scd.2012.0594","article-title":"Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.","volume":"22","author":"Menard","year":"2013","journal-title":"Stem Cells Dev."},{"key":"B20","first-page":"1","article-title":"Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: results at 12-months follow-up: a systematic review of the literature.","volume":"27","author":"Migliorini","year":"2019","journal-title":"Arch Orthop. Trauma Surg."},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9472","article-title":"Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs.","volume":"6","author":"Phinney","year":"2015","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/stem.2575","article-title":"Concise review: MSC-derived exosomes for cell-free therapy.","volume":"35","author":"Phinney","year":"2017","journal-title":"Stem Cells"},{"key":"B23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbmt.2010.04.014","article-title":"Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.","volume":"17","author":"Prasad","year":"2011","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2019.04.002","article-title":"Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives.","volume":"14","author":"Regmi","year":"2019","journal-title":"Eur J Cell Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000447458","article-title":"Mesenchymal stem\/stromal cells in regenerative medicine: can preconditioning strategies improve therapeutic efficacy?","volume":"43","author":"Schafer","year":"2016","journal-title":"Transfus. Med. Hemother."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-146","article-title":"Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells.","volume":"11","author":"Siegel","year":"2013","journal-title":"BMC Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1182\/blood-2010-08-304287","article-title":"CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization.","volume":"117","author":"Tormin","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.bbmt.2018.07.015","article-title":"Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: a survey among centers affiliated with the european society for blood and marrow transplantation.","volume":"24","author":"Trento","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3346-z","article-title":"MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I\/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.","volume":"20","author":"Uccelli","year":"2019","journal-title":"Trials"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1089\/scd.2013.0016","article-title":"Mesenchymal stromal cell characteristics vary depending on their origin.","volume":"22","author":"Wegmeyer","year":"2013","journal-title":"Stem Cells Dev."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040982","article-title":"Enhancement of functionality and therapeutic efficacy of cell-based therapy using mesenchymal stem cells for cardiovascular disease.","volume":"20","author":"Yun","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:53:10Z","timestamp":1696233190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":31,"alternative-id":["10.3389\/fcell.2020.00458"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.00458","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"article-number":"458"}}